Chemotherapy of malignant fibrous histiocytoma of bone

Earl, HM; Pringle, J; Kemp, H. B. S.; Morittu, L.; Miles, David; Souhami, Robert L.

doi:10.1093/oxfordjournals.annonc.a058521

Cited by 18 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, local recurrence or distal metastases occur within 5 years in approximately 70% of patients with highgrade lesions treated in this way. 9 Thus, the 5-year survival rate is only 10% to 30%. 10 Recently, several studies have reported that adjuvant chemotherapy improved survival rates from 10-30% to 50-60%.…”

Section: Discussionmentioning

confidence: 99%

Scalp metastasis from malignant fibrous histiocytoma of bone

Kubo

Shimose

Matsuo

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Scalp metastasis from malignant fibrous histiocytoma of bone

Kubo

Shimose

Matsuo

et al. 2008

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…As shown in Table 4, several studies report similar survival and pathological response rates to CT in patients with UPS of bone or osteosarcoma, 15,[31][32][33][34] while others report consistently poorer chemosensitivity of bone UPS regardless of the number of drugs and the dose intensity. In the recent study reported by Toronto Sarcoma Program, high degree of necrosis on final pathology and receipt of CT were associated with improved survival in 106 patients with UPS/MFH (41.5%), LMS (20.8%), fibrosarcoma (11.3%) and other rare sarcoma of bone subtypes (12.3%).…”

Section: Discussionmentioning

confidence: 99%

Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group

Boudou‐Rouquette

Martin

Kempf

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

The benefit of chemotherapy (CT) in rare bone sarcomas is not documented in prospective studies. Our retrospective study from the French sarcoma network for bone tumors ResOs was performed in adult patients (pts) from 1976 to 2014, with histologically verified diagnosis of leiomyosarcomas (LMS), undifferentiated pleomorphic sarcoma (UPS) or radiation-associated sarcomas of bone. The median follow-up was 4.7 years (95% CI: 3.7-6.5). Clinical features, treatment modalities and outcomes were recorded and analyzed from 145 pts (median age 53 years [range 20-87]). Site of disease was extremities (66%) or axial skeleton (34%), 111 (77%) presented with localized and potentially resectable disease. The most common histological subtypes were UPS (58%) and LMS (33%); 58% were high-grade tumors. Surgery was performed in 127 pts. In the 111 localized pts, 28 pts (25%) underwent upfront surgery or exclusive radiotherapy (RT; >50 Gy) without CT, whereas 83 pts (75%) received either neoadjuvant (n = 26) or adjuvant CT (n = 13) or both (n = 44). Neoadjuvant and adjuvant CT was mostly doxorubicin-based (95%/86%) and cisplatin-based (67%/63%). R0 resection was achieved in 59 pts, and a good histological response in 15 patients (25%). Adjuvant RT was performed in 24 (22%) pts. For the whole cohort (n = 145), the 5-year overall survival (OS) rate was 53% [42; 62]. In univariate analysis, age ≤ 60 was associated with a longer disease-free survival (DFS) (P = .0436). Neoadjuvant and adjuvant CT tended to be associated with better DFS (P = .056) with no significant impact on OS in this retrospective series.

show abstract

“…Most published studies have described specific types of spindle cell sarcomas of bone and are either case reports or case series limited by sample size, and do not evaluate prognostic factors. 8,[17][18][19][20][21] A paper from the Mayo Clinic reported 225 fibrosarcomas of bone diagnosed over an 85-year period, but only 92 patients with available clinical and follow-up data were analysed. 2 The reported disease-free survival for the whole group at five years was 28%, but increased to 45% for patients diagnosed after 1980.…”

Section: Discussionmentioning

confidence: 99%

The ‘other’ bone sarcomas

Pakos

Grimer

Peake

et al. 2011

The Journal of Bone and Joint Surgery. British volume

View full text Add to dashboard Cite

We aimed to identify the incidence, outcome and prognostic factors associated with spindle cell sarcomas of bone (SCSB). We studied 196 patients with a primary non-metastatic tumour treated with the intent to cure. The results were compared with those of osteosarcoma patients treated at our hospital during the same period. The overall incidence of SCSB was 7.8% of all patients with a primary bone sarcoma. The five- and ten-year survival rates were 67.0% and 60.0%, respectively, which were better than those of patients with osteosarcoma treated over the same period. All histological subtypes had similar outcomes. On univariate analysis, factors that were significantly associated with decreased survival were age > 40 years, size > 8 cm, the presence of a pathological fracture, amputation, involved margins and a poor response to pre-operative chemotherapy. Multivariate analyses showed that age > 65 years, amputation and involved margins were all statistically significant prognostic factors. Involved margins and poor response to pre-operative chemotherapy were associated with an increased risk of local recurrence. SCSB has a better prognosis than osteosarcoma when matched for age. Most prognostic factors for osteosarcoma also seem to apply to SCSB. Patients with SCSB should be treated in the same way as patients of the same age with osteosarcoma.

show abstract

Chemotherapy of malignant fibrous histiocytoma of bone

Abstract: This study confirms previous reports that MFHB is a chemosensitive tumour. In view of its rarity collaborative trials are needed to establish the optimum drug treatment including drug selection dose and duration.

Cited by 18 publications

References 17 publications

Scalp metastasis from malignant fibrous histiocytoma of bone

Scalp metastasis from malignant fibrous histiocytoma of bone

Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group

The ‘other’ bone sarcomas

Contact Info

Product

Resources

About